Quick Facts

• Targeted Conditions: Certain fungal infections of the skin and nails.
• Therapeutic Scope: Tinea infections, including ringworm, athlete's foot, and jock itch.
• Purpose: To manage and resolve specified fungal infections.

---

What Funguard Treats: Main Uses and Benefits

Funguard is an established treatment option indicated for managing a range of fungal infections. Its use is generally restricted to specific infections of the skin and nails.

This medication is primarily authorized to address Tinea infections. These include tinea corporis (commonly known as ringworm), tinea cruris (jock itch), and tinea pedis (athlete's foot). The medication is also utilized to manage onychomycosis, a fungal infection affecting the fingernails or toenails. In certain presentations, it may be used to address tinea capitis (scalp ringworm), particularly when topical treatments are not suitable or effective.

Funguard works to manage the fungal presence in the affected areas. Completing the full prescribed course is essential to achieve the expected outcome in the treatment of these conditions. The therapeutic benefits relate to the resolution of the infectious process and the associated physical symptoms.

Funguard (Micafungin) eligibility is defined by official regulatory documents based on contraindications, age, organ function, and reproductive status.

Contraindications

• Hypersensitivity: The medicine is contraindicated in patients with a known severe allergy to micafungin sodium, any component of the injection, or any other drug in the echinocandin class of antifungals.

---

Age and Organ Function Restrictions

Population Group	Eligibility Status (Regulatory Basis)
Adults and Children geq 4 months	Approved for primary systemic indications.
Infants < 4 months	Use not established for Candida infections involving the central nervous system (CNS), such as meningoencephalitis or ocular dissemination.
Severe Hepatic Impairment	Use not recommended due to insufficient safety data and a potential liver tumor risk seen in animal studies. Monitoring is essential.
Renal Impairment	No dose adjustment is required in patients with severe renal impairment.

---

Other Conditional Limitations

Pregnancy and Lactation: Use during pregnancy is not recommended unless clearly necessary, based on animal toxicity findings. For lactation, a decision must be made to discontinue the medicine or discontinue breastfeeding, as the drug's presence in human milk is unknown.

Interactions with other medicines and products

Funguard’s officially documented interaction profile details specific constraints related to co-administration and physical compatibility, based strictly on government regulatory labeling.

Contraindicated Combinations

Funguard (Micafungin) is formally contraindicated in individuals with a known hypersensitivity to the active substance, any of its components, or to other medicines classified as echinocandins.

Exposure-Altering Co-administrations

Regulatory documents state that co-administration with Funguard increases the plasma concentrations of certain other medicines. This pharmacokinetic interaction requires monitoring for toxicity and potential dosage reduction of the co-administered drug, specifically for Sirolimus and Nifedipine. Similarly, close monitoring and potential dose reduction are required when co-administering Itraconazole. Conversely, Funguard’s own systemic exposure remains largely unchanged when combined with many common agents, including cyclosporine, tacrolimus, fluconazole, and rifampin, meaning no Funguard dose adjustment is necessary.

Pharmacodynamic and Procedural Restrictions

Specific pharmacodynamic risks are officially documented, such as the increased risk of nephrotoxicity and ototoxicity observed with Voclosporin. Co-administration with Prednisolone has also been associated with reports of acute intravascular hemolysis, necessitating close observation. A strict procedural rule mandates that Funguard must not be mixed or co-infused with other medicinal products due to the risk of physical incompatibility, specifically precipitation. No significant interaction with food, alcohol, or herbal products is formally documented in the regulatory labeling.

Selective Inhibition of Fungal Cell Wall Synthesis

Funguard's mechanism of action involves achieving non-competitive inhibition of the boldsymbolbeta-(1,3)-D-glucan synthase enzyme complex. This enzyme is localized exclusively in the fungal plasma membrane. The drug's interaction prevents the enzyme from performing its function of synthesizing beta-(1,3)-D-glucan polymers, which are fundamental scaffolding components required for fungal cell wall structure. This molecular step modifies an early process in the fungal structural pathway, leading to the physiological consequence of structural vulnerability.

Cascade Leading to Osmotic Lysis

The resulting deficit of the critical beta-(1,3)-D-glucan component renders the fungal cell wall unstable and structurally compromised. This lack of rigidity causes the fungal cell to be unable to withstand internal osmotic pressure. The consequence is a direct lytic effect where the cell ruptures, initiating cellular demise. This mechanistic domain directly links structural failure to the subsequent lytic effect on the pathogenic organism due to the target's unique presence in the fungal kingdom.

Funguard (terbinafine) is an antifungal medication typically used to treat various skin conditions like athlete's foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis). The proper application technique is essential for successful treatment and to prevent the recurrence of the infection.

Application Instructions

Step	Instruction
1. Preparation	Clean the affected skin area thoroughly with mild soap and water. It is critical to dry the area completely before application, as moisture can encourage fungal growth.
2. Application	Wash your hands. Apply a thin layer of the cream to cover the affected area and the surrounding skin gently. For example, for athlete's foot, ensure you apply the cream between the toes. Wash your hands immediately after application, unless the hands are the treatment site.
3. Frequency	Apply the medication twice daily, usually in the morning and evening, or as directed by a healthcare professional.

Treatment Duration and Precautions

The length of treatment varies depending on the type and severity of the infection. For jock itch and ringworm, treatment may typically last for one to four weeks, while athlete's foot often requires four weeks of daily use. It is crucial to continue using Funguard for the full duration of treatment, even if symptoms like itching and redness have disappeared, to ensure the infection is fully cleared and to minimize the risk of relapse.

• External Use Only: This medication is for topical, external use only. Avoid contact with the eyes, mouth, and other mucous membranes. Rinse thoroughly with water if accidental contact occurs.
• Do Not Cover: Unless specifically advised by a doctor, do not cover the treated skin area with an occlusive (airtight) bandage or non-breathable dressings.
• Lifestyle: Wear loose-fitting, clean cotton clothing to promote ventilation of the affected area, and change socks and undergarments daily.

Research Evidence / Overview of Studies for Funguard

The research for Funguard (Micafungin) is primarily documented in large clinical trials reviewed by regulators worldwide. This evidence base explores its use in studying severe fungal infections, focusing on what was examined, the patterns observed, and what remains uncertain.

---

Evidence for Treating Invasive Candida Infections

Research exploring the use of Funguard in patients with conditions such as bloodstream Candida infections (candidemia) and other invasive forms mainly consists of large, randomized controlled trials (RCTs). Researchers designed these studies to measure overall treatment success, which is a composite outcome related to physical discomfort and outcomes related to the status of the fungal organism. Studies monitored how symptoms evolved in the observed populations by observing patterns when Funguard was studied alongside other treatments.

Long-term effects are not fully established; follow-up durations were limited, often extending only up to six weeks after treatment concluded. Furthermore, there is limited information for long-term outcomes for the treatment of certain complex anatomical sites, such as bone or central nervous system infections.

---

Evidence for Preventing Fungal Infections (Prophylaxis)

Funguard was evaluated in clinical research exploring its use for prevention against Candida infections for specific patient groups. These studies generally involved randomized controlled trials comparing Funguard against another antifungal drug or a placebo, often conducted during periods where patients were immunosuppressed. The main objective was to monitor the absence of a proven fungal infection over a defined time interval. Findings indicate patterns related to the incidence of infection associated with the use of Funguard in the studied groups.

---

Areas of Research Uncertainty and Study Gaps

Evidence quality varies across studies, and certainty remains low in certain areas. Key limitations include that comparative evidence is lacking for some of the newer antifungal combinations. Research highlights what is known, but there is still uncertainty regarding the use of Funguard for infections in certain anatomical sites. The current findings describe group patterns, not personal outcomes, and evidence for certain subgroups of patients remains limited. Research does not determine whether an individual will respond similarly to the group patterns observed in trials.

Common questions about Funguard (FAQ)

---

Q: Is Funguard a type of antibiotic?

Funguard is generally classified as an antifungal medication. Antifungals work specifically against fungal infections, whereas antibiotics are typically used to treat bacterial infections.

Q: Can I stop taking Funguard once my symptoms improve?

It is important to continue taking Funguard for the full duration prescribed by a healthcare provider, even if symptoms appear to clear up earlier. Stopping treatment prematurely may allow the infection to return.

Q: What should I do if I miss a dose of Funguard?

If a dose of Funguard is missed, it should generally be taken as soon as the patient remembers. However, if it is almost time for the next scheduled dose, the patient should skip the missed dose and resume the regular dosing schedule. A patient should consult their healthcare provider or pharmacist for specific guidance.

Q: Does Funguard cause weight gain?

Weight changes are not commonly listed as a primary side effect for Funguard in product labeling. If a patient is concerned about unexpected weight changes while taking this medication, they should discuss this with a healthcare professional.

How to Store and Dispose of Funguard (Micafungin)

Funguard, supplied as a lyophilized powder, must be managed according to specific regulatory rules for storage, stability, and disposal.

Storage and Stability Conditions

Product State	Temperature and Protection	Stability Limit
Unopened Vial	Controlled Room Temperature (20 C to 25 C)	Until expiration date
Prepared Solutions	Room Temperature (25 C) and Protect from Light	Total storage time must not exceed 24 hours

All medicine must be stored out of the sight and reach of children.

Handling and Disposal Requirements

Funguard is a single-use vial, and any unused portion must be discarded. Preparation must follow aseptic technique, and the vial must not be vigorously shaken. If the solution shows particulate matter or discoloration, it must not be used. Disposal of the contents and container must be done in accordance with applicable local laws and regulations, avoiding release into the environment, including surface water and drains.